Using peptide modifiers nucleic acids as gene-expression to reduce β-amyloid levels

The deposition of amyloid beta peptide (Abeta) is an early and critical aspect of Alzheimer's disease. Abeta is formed by the cleavage of amyloid precursor protein (APP). Studies of familial forms of Alzheimer's disease indicate that elevated secretion of Abeta, particularly Abeta((1-42)), is likely to be an etiologic agent in the disease. Abeta((1-42)) is known to cause fibril formation and at elevated levels increases aggregation, which can lead to neuronal death. It has, therefore,been hypothesized that if the levels of Abeta, particularly Abeta((1-42)), could be reduced that onset of Alzheimer's disease could be slowed or possibly prevented. We, therefore, propose using PNAs targeted to APP to decrease plasma and brain levels of Abeta((1-40)) and Abeta((1-42)). This research project is designed to expand upon the discovery in our laboratory that systemic administration of antisense or antigene treatments utilizing peptide nucleic acids (PNAs) can be used to target and shut down proteins. Antisense strategies are methods of specifically targeting a particular protein by inhibiting translation by complementary binding to mRNA, while antigene methods inhibit transcription by complementary binding to DNA. For experiments involving antisense strategies, there are several advantages to using PNAs as opposed to the traditional oligonucleotide approaches. We initially preformed our studies in rats and identified a PNA sequence that was able to significantly reduce the levels of Abeta((1-41)) in rat brain compared to vehicle control rats. We have switched to mice so that we can prepare to perform our experiments in a transgenic animal model of Alzheimer's disease. We have, however, run into several technical difficulties with using mice compared to rats. In spite of this, we have identified one PNA sequence that specifically lowers mouse brain Abeta((1-40)) Abeta((1-42)) by 37% and 47%, respectively.